FRFlavia Karine Rigo

Flavia Karine Rigo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Flavia Karine Rigo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Full-spectrum cannabidiol-rich oil modulates behavior and neurochemical alterations in a rodent model of maple syrup urine disease

    by Isabela da Silva Lemos, Sasckia Duarte, Meline Oliveira dos Santos Morais, Carolina Giassi Alano, Laura Schmidt Quinsani, Rafaela Tezza Matiola, Flávia Saccon Niero, Lucas Candido Pedro, Zilli Réus, Flavia Karine Rigo, et al.

  • Behavioral Alterations and Cholinergic Modulation in Zebrafish Acutely Exposed To Tyrosine

    by Isabela da Silva Lemos, Francine Fiorot Prando de Vasconcelos, Guilherme da Silva Lodetti, Carolina Giassi Alano, Flávia Karine Rigo, Rahisa Scussel, Fabio Henrique Baia, Eduardo Pacheco Rico, Emilio Luiz Streck

    Tyrosinemia type II (Richner–Hanhart syndrome) is a rare disorder caused by mutations in the TAT gene, leading to elevated blood tyrosine and impaired metabolism. It presents with oculocutaneous symptoms, retinal tyrosine crystals, and neurological issues. Elevated tyrosine disrupts brain metabolism, neurotransmitters, and neurotrophic factors, causing neuroinflammation and affecting brain function. The exact mechanism of neurological damage is unclear, and the impact of dietary intervention on cognition is uncertain. While rodent models are commonly used, zebrafish are emerging as a cost-effective, genetically similar alternative for studying tyrosinemia type II. Thus, this study aims to determine whether acute exposure of zebrafish to elevated tyrosine concentrations can reproduce early central nervous system alterations associated with tyrosinemia type II. Zebrafish were exposed via immersion to 1 mM or 2 mM tyrosine for 1–24 h, with a total of 180 animals used across assays. Behavioral analysis was conducted using the novel tank test, and cholinergic and oxidative stress markers were assessed. Brain tyrosine levels were measured centrally. Exposure to 1 mM tyrosine for 24 h resulted in the highest brain accumulation, suggesting a non-linear dose-response. Behavioral testing revealed decreased locomotor activity and exploratory behavior, and ChAT activity was reduced in both exposure groups. No significant changes were observed in oxidative stress or protein damage. These findings indicate that acute tyrosine exposure induces early behavioral and cholinergic alterations without detectable oxidative stress, supporting the use of zebrafish as a preliminary model to study early neurochemical disturbances such in tyrosinemia type II. Further studies should explore different life stages, sex-specific responses, chronic exposure, and precise tyrosine kinetics, including potential non-linear effects due to the LAT1 transporter, to clarify mechanisms underlying neurotoxicity and improve translational relevance. Graphical Abstract

  • Cannabis Extracts and Their Cytotoxic Effects on Human Erythrocytes, Fibroblasts, and Murine Melanoma

    by Patrícia Rossa Milanez, Falaise Matos Ramos da Silva, Rahisa Scussel, Maria Eduarda de Melo, André Bittencourt Martins, Ricardo Andrez Machado-De-Ávila, James William Barlow, Paulo Emílio Feuser, Flavia Karine Rigo, Patrícia de Aguiar Amaral


  • Anti-genotoxic and anti-mutagenic effects of melatonin supplementation in a mouse model of melanoma

    by Luiza Martins Longaretti, Jéssica Aparecida Luciano, Giulia Strapazzon, Maiara Pereira, Adriani Paganini Damiani, Paula Rohr, Flávia Karine Rigo, Camila Alves de Oliveira, Bethina Trevisol Steiner, Thais Ceresér Vilela, et al.

    Melanoma, an aggressive skin cancer originating from melanocytes, can metastasize to the lungs, liver, cortex, femur, and spinal cord, ultimately resulting in DNA mutagenic effects. Melatonin is an endogenous hormone and free radical scavenger that possesses the ability to protect the DNA and to exert anti-proliferative effects in melanoma cells. The aim of this study was to evaluate the effects of B16F10 melanoma cells and the effects of melatonin supplementation on genotoxic parameters in murine melanoma models. Thirty-two male C57Bl/6 mice were divided in the following four groups: PBS + vehicle (n = 6), melanoma + vehicle (n = 10), PBS + melatonin (n = 6), and melanoma + melatonin (n = 10). The melanoma groups received a B16F10 cell injection, and melatonin was administered during 60 days. After treatment, tumor sizes were evaluated. DNA damage within the peripheral blood, lungs, liver, cortex, and spinal cord was determined using comet assay, and the mutagenicity within the bone marrow was determined using the micronucleus test. B16F10 cells effectively induced DNA damage in all tissues, and melatonin supplementation decreased DNA damage in the blood, liver, cortex, and spinal cord. This hormone exerts anti-tumor activity via its anti-proliferative, antioxidative, and pro-apoptotic effects. As this result was not observed within the lungs, we hypothesized that melatonin can induce apoptosis in cancer cells, and this was not evaluated by comet assay. This study provides evidence that melatonin can reduce the genotoxicity and mutagenicity caused by B16F10 cells.